The current recommendation is to perform re-resection for select patients with incidentally discovered gallbladder cancer. The optimal time interval for re-resection for both patient selection and long-term survival is not known.
T he sixth most common gastrointestinal cancer, gallbladder carcinoma is a rare disease with a poor overall prognosis. 1, 2 Resection is the only potentially curative treatment option, yet reported survival rates following surgery vary greatly, from 10% to 100% at 5 years, depending on tumor biology, stage of disease, and extent of resection. [2] [3] [4] Approximately 50% to 70% of gallbladder cancers are found incidentally during or after an elective cholecystectomy for presumed benign disease, which represents 0.7% of all cholecystectomy specimens. [5] [6] [7] Current management guidelines for incidental gallbladder cancer (IGBC) recommend re-resection for T1b, T2, and T3 lesions, unless contraindicated by advanced disease or poor performance status. 8 However, to our knowledge, there are few data on the timing of re-resection, which can vary between 1 day and more than 2 years following the initial cholecystectomy. 9 In the benign setting, most surgeons generally elect to reoperate either within the first 7 to 10 daysbefore the inflammatory processes have peaked-or after approximately 4 to 6 weeks, when these processes have begun to subside. In malignancy, tumor biology, in addition to technical considerations, plays an important role in defining the optimal timing of reoperation.
In several other cancers, such as esophageal and rectal cancers, the timing of definitive surgery following the initial treatment has been studied in detail, yet has primarily focused on the timing of surgery following neoadjuvant radiation. 10, 11 In IGBC, to our knowledge, no study has examined the effect of the timing of reoperation after the initial cholecystectomy on outcomes. The purpose of this study was to assess the association of time interval from the initial cholecystectomy to reoperation with overall survival (OS).
Methods

Study Population
The US Extrahepatic Biliary Malignancy Consortium is a collaboration of 10 high-volume academic institutions: Emory University, Johns Hopkins University, New York University, The Ohio State University, Stanford University, University of Louisville, University of Wisconsin, Vanderbilt University, Wake Forest University, and Washington University in St Louis. All patients with IGBC who underwent reoperation from January 1, 2000, to December 31, 2014, were assessed. Only patients with IGBC who had information regarding the dates of their initial cholecystectomy and reoperation were included. Cases in which the diagnosis of IGBC was made intraoperatively and the definitive resection was performed under the same anesthesia were excluded. Pertinent baseline demographic, preoperative, intraoperative, pathologic, and postoperative data were recorded. Pathology review was performed by experienced gastrointestinal pathologists at each institution, and staging was assigned as per American Joint Committee on Cancer 7th edition guidelines.
12 Data regarding neoadjuvant and adjuvant therapy, disease recurrence, and survival were additionally collected. Survival information was verified with the Social Security Death Index when necessary. Institutional review board approval was obtained at each institution prior to data collection. Because this study involved only retrospective medical record review and posed minimal risk to patients, a waiver of consent was obtained at each institution. Descriptive and comparative analyses were performed on the entire cohort. Thirty-day postoperative deaths (n = 4) were excluded for all survival analyses. Overall survival was calculated from the date of reoperation to the date of death or last follow-up. To account for potential length-time bias between groups, OS was also calculated from the date of the initial cholecystectomy to the date of death or last follow-up.
Time Interval Groups
The time interval from the date of the initial cholecystectomy to the date of reoperation was calculated for all patients. Patients were then separated into 3 groups according to their time interval to reoperation: group A (less than 4 weeks), B (4 to 8 weeks), and C (more than 8 weeks). The primary objective was to assess the difference in OS between groups to identify the optimal timing for reoperation and reresection in patients with IGBC.
Statistical Analysis
All statistical analysis was performed using SPSS version 22.0 software (IBM Inc). The t test or 1-way analysis of variance was used to compare continuous variables, and χ 2 analysis was used for categorical variables where indicated. Kaplan-Meier survival plots were calculated for OS. Univariable and multivariable Cox regression analyses were performed to assess the effect of time interval group on OS in the context of other clinically relevant clinicopathologic features. Statistical significance for each end point was predefined as 2-tailed P < .05.
Results
Of 449 patients with gallbladder cancer, 266 cases (59%) were discovered incidentally. The date of the initial cholecystectomy was not available for 33 patients, and in 26 patients, the definitive resection was performed at the time of incidental discovery, leaving 207 (46%) for inclusion in
Key Points
Question Is there an association between time interval from the initial cholecystectomy to reoperation and overall survival?
Findings In this multi-institutional cohort study of 207 patients who underwent reoperation for incidental gallbladder cancer, reoperation between 4 and 8 weeks after the initial cholecystectomy was associated with improved median overall survival (40.8 months) compared with reoperation less than 4 weeks (17.4 months) and greater than 8 weeks (22.4 months).
Meaning Reoperation between 4 and 8 weeks after the initial cholecystectomy appears to be the optimal time interval for re-resection in incidental gallbladder cancer.
analysis. Among the entire cohort, the median time to reoperation was 7.4 weeks (interquartile range, 5.0-10.7). Twenty-five patients (12%) underwent reoperation less than 4 weeks (group A), 91 (44%) between 4 weeks and 8 weeks (group B), and 91 (44%) greater than 8 weeks (group C) after their initial cholecystectomy. Comparative analyses of clinicopathologic factors across groups are shown in Table 1 . There was no difference in baseline demographics or underlying comorbidities between groups. Patients in group A tended to be more likely to have undergone the initial cholecystectomy at their respective participating institution (24%), while patients in groups B and C tended to have undergone the initial cholecystectomy at outside hospitals (91% and 90%, respectively), although this was not statistically significant (P = .09). A similar proportion of patients in each group had locoregional residual or distant disease at the time of reoperation and underwent completed resections. There was no difference in the extent of the resection performed, with most patients undergoing the recommended partial hepatectomy (segments IVb and V) with portal lymph node dissection in all groups (96%, 87%, and 93%, respectively; P = .29). There was no difference between groups in margin status, T stage distribution, histologic grade, lymphovascular invasion, perineural invasion, or the presence of positive lymph nodes.
There was no difference in the incidence of major postoperative complications between groups (P = .24). Seven patients (8%) in group C received neoadjuvant therapy compared with zero patients in groups A and B (P = .01). A similar proportion of patients received adjuvant therapy in all groups.
Median follow-up was 13.9 months (interquartile range, 2.7-37. Univariable and multivariable Cox regression analyses for OS calculated from the date of reoperation are shown in Table 2 . Time interval group (A and C vs B), advanced T stage (T3/4 vs T2), margin positivity, the presence of residual disease at reoperation, and lymph node positivity were all associated with worse survival on univariable analysis. Only time interval group, R2 resection, and advanced T stage were associated with worse survival on multivariable analysis. On multivariable Cox regression analysis calculating OS from the date of the initial cholecystectomy, group A (hazard ratio, 2.82; 95% CI, 1.33-5.97; P = .007) and group C (hazard ratio, 1.89; 95% CI, 1.07-3.33; P = .03) were still associated with worse survival compared with group B, as were advanced Tstage and R2 resection.
Discussion
Gallbladder cancer is a rare and aggressive malignancy with a poor prognosis. Resection is the only potentially curative treatment option, and the timing of resection has been shown to be an important factor in determining outcomes-gallbladder cancer diagnosed in patients incidentally, which accounts for most cases, has better survival rates than gallbladder cancer diagnosed in patients only after the signs and symptoms of malignancy become apparent. 7 Once IGBC is discovered, reresection is the recommended treatment strategy for patients with T1b, T2, and T3 tumors. 8 The choice of timing for reoperation is largely dictated by the waxing and waning of the inflammatory process to minimize complications and maximize patient safety. However, just as the timing of diagnosis of gallbladder cancer can translate to survival, so too may the timing of re-resection be an important, and heretofore underappreciated, determinant of outcomes in patients with IGBC. Indeed, the optimal timing of re-resection in IGBC that balances both technical considerations and tumor biology is currently not known.
In the current study, 207 patients underwent reoperation for IGBC. Baseline demographics, clinicopathologic characteristics, and outcomes of the entire cohort were similar to those in previous studies on IGBC. [5] [6] [7] 9, 13, 14 Overall, the median time to reoperation was 7.4 weeks (interquartile range, 5.0-10.7). This is in line with the general global practice patterns for this disease. 7,9,13-15 Twenty-five patients (12%) underwent reoperation within 4 weeks (group A), 91 (44%) between 4 weeks and 8 weeks (group B), and 93 patients (44%) beyond 8 weeks (group C) after the initial cholecystectomy. The groups were very similar with regard to baseline demographics and clinicopathologic characteristics. There were no differences in the presence of locoregional residual or distant disease at the time of reoperation, the percentage of aborted procedures and R2 resections, or the incidence of major complications between groups. Important prognostic factors other than margin status, such as T stage, grade, lymphovascular invasion, perineural invasion, and lymph node status were also similar between groups.
Based on data from the current study, it appears that reoperation between 4 and 8 weeks (group B) is the optimal time interval for re-resection in patients with IGBC. Group B had significantly better survival than groups A and C on KaplanMeier, univariable Cox regression, and multivariable Cox regression analyses. Even when excluding patients with aborted procedures and R2 resections, and calculating OS from the date of the initial cholecystectomy, group B patients still had better survival than those in both A and C. The possible reasons for this are many. First, reoperating earlier than 4 weeks may not allow for complete tumor evaluation and staging. Preliminary results based on frozen section analysis can be difficult to interpret and may be unreliable in the setting of acute inflammation. Furthermore, inflammation in the operative field can make visualization of important structures on crosssectional imaging near impossible in the early postoperative period. Thus, it may take several weeks for adequate TNM and clinical staging to be completed, and rushing to the operating room may be doing so without all the information. Second, reoperating outside the 4-to 8-week window may be suboptimal from a tumor biology standpoint. Reoperation too early (before 4 weeks) may not allow sufficient time for subclinical disease, which was likely already present at the time of diagnosis, to be appreciated. Conversely, reoperation too late (after 8 weeks) may allow too much time for disease dissemination. Although the percentage of patients with locoregional or distant disease at the time of reoperation was similar between groups B and C, this finding likely reflects selection bias and should be interpreted with caution-only patients who survived long enough, without evidence of locally advanced or distant disease preoperatively, underwent reoperation and were included in this study. Given this, one might expect patients in group C, who represent the "hearty survivors," to have better survival than those in groups A and B; yet, group B patients still had better survival outcomes than group C patients, which may reflect more advanced subclinical disease in the latter group that might have been prevented had these patients been reoperated on sooner.
There are several limitations to this study. First, by including only patients who underwent reoperation, there is an inherent selection bias in this study, as previously discussed. However, this is not uncommon in studies examining the effect of surgery timing on patient outcomes, particularly in a tertiary care setting in which most patients are referred from outside facilities after diagnosis, as was the case in this study. Despite this bias, groups were still wellmatched for most baseline and clinicopathologic factors. Second, the retrospective nature of the study makes recurrence and disease-specific survival information difficult to capture. However, this study incorporates data from 10 high-volume, geographically dispersed academic institutions, which more closely represents the disease characteristics and general practice patterns of the United States and eliminates single-institution bias. In addition, given the aggressive nature of and poor prognosis associated with gallbladder cancer, OS is a good surrogate for disease-specific survival in most cases.
Conclusions
In conclusion, this is one of the largest series that examines patients who underwent reoperation for IGBC and, to our knowledge, the only study that assesses the effect of time from the initial cholecystectomy to reoperation on these patients' survival. Between 4 and 8 weeks appears to be the optimal time interval for re-resection that balances both technical considerations and tumor biology in patients with IGBC. The authors are to be commended for providing the largest analysis of incidental gallbladder cancer specifically evaluating the timing of reoperation, but the conclusions from their retrospective analysis should be met with caution.
While we agree with the authors that early reoperation risks considerable inflammation that may compromise reliable preoperative clinical staging and increase operative difficulty, it is unlikely that these factors are sufficiently mitigated in the 4-to 6-week interval. Consequently, reoperation during this early 2-week phase in the 4-to 8-week interval, as the authors seem to recommend, would also generally be considered ill-advised.
To explain their findings, the authors invoke the wellaccepted assertion that time is a surrogate for tumor biology.
They suggest that early reoperation (less than 4 weeks) may not allow for an adequate assessment of advanced subclinical disease, while late reoperation (more than 8 weeks) may allow for dissemination of subclinical disease that remains undetected, explaining the inferior outcomes in these 2 groups. While it is undeniable that time allows for manifestation of subclinical disease, it is difficult to reconcile the authors' contention that a few extra weeks of early observation allowed the identification of patients with initially advanced subclinical disease, while a similar number of weeks in the later period led to lower curability of disease without clinically detectable progression.
On closer examination of the data, the relatively small number of patients in each group potentially limits the power to detect important differences that may explain the results. As an example, the presence of T3/4 tumors, 1 of the only 2 significant independent predictors of survival apart from the time interval to reoperation itself, was found in only 30% of patients in group B but 46% and 44% of patients in groups A and C, respectively. Comparison of group B with groups A and C in aggregate might yield different conclusions.
As with any retrospective study, the inherent bias regarding selection of patients for reoperation, as well as unknowable factors affecting the timing of reoperation, should lead to a softer conclusion that reoperation at 4 to 8 weeks was associated with better outcomes and not necessarily responsible for them. We credit the authors for this important work. A prospective validation is essential to incorporate these findings into practice recommendations.
